Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/191021
Title: A C˄S-cyclometallated gold(III) complex as novel antibacterial candidate against drug-resistant bacteria
Author: Ratia, Carlos
Cepas, Virginio
Soengas, Raquel
Navarro, Yolanda
Velasco de Andrés, María
Iglesias, Maria José
Lozano, Francisco
López Ortiz, Fernando
Soto, Sara M.
Keywords: Resistència als medicaments
Medicaments antibacterians
Crisoteràpia
Drug resistance
Antibacterial agents
Chrysotherapy
Issue Date: 3-Mar-2022
Publisher: Frontiers Media
Abstract: The worldwide emergence and spread of infections caused by multidrug-resistant bacteria endangers the efficacy of current antibiotics in the clinical setting. The lack of new antibiotics in the pipeline points to the need of developing new strategies. Recently, gold-based drugs are being repurposed for antibacterial applications. Among them, gold(III) complexes have received increasing attention as metal-based anticancer agents. However, reports on their antibacterial activity are scarce due to stability issues. The present work demonstrates the antibacterial activity of the gold(III) complex 2 stabilized as C∧S-cycloaurated containing a diphenylphosphinothioic amide moiety, showing minimum inhibitory concentration (MIC) values that ranged from 4 to 8 and from 16 to 32 mg/L among Gram-positive and Gram-negative multidrug-resistant (MDR) pathogens, respectively. Complex 2 has a biofilm inhibitory activity of only two to four times than its MIC. We also describe for the first time a potent antibacterial synergistic effect of a gold(III) complex combined with colistin, showing a bactericidal effect in less than 2 h; confirming the role of the outer membrane as a permeability barrier. Complex 2 shows a low rate of internalization in Staphylococcus aureus and Acinetobacter baumannii; it does not interact with replication enzymes or efflux pumps, causes ultrastructural damages in both membrane and cytoplasmic levels, and permeabilizes the bacterial membrane. Unlike control antibiotics, complex 2 did not generate resistant mutants in 30-day sequential cultures. We detected lower cytotoxicity in a non-tumoral THLE-2 cell line (IC50 = 25.5 μM) and no acute toxicity signs in vivo after an i.v. 1-mg/kg dose. The characterization presented here reassures the potential of complex 2 as a new chemical class of antimicrobial agents.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fmicb.2022.815622
It is part of: Frontiers in Microbiology, 2022, vol. 13
URI: http://hdl.handle.net/2445/191021
Related resource: https://doi.org/10.3389/fmicb.2022.815622
ISSN: 1664-302X
Appears in Collections:Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)
Articles publicats en revistes (Biomedicina)

Files in This Item:
File Description SizeFormat 
718500.pdf5.88 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons